Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM), to support the 2^nd Annual Spinal Cord Injury Investor Symposium ("2^nd SCIIS"). The 2^nd SCIIS builds upon a successful inaugural event held in 2023 and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI). This year’s event aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430502008/en/

“This conference was created to foster engagement and collaboration, as well as to bring innovation and modernization to approaches and treatments for spinal cord injury. We are proud to again have the support of CIRM and other leading entities in spinal cord injury advocacy and therapeutic development, as we work to bring greater awareness to the field,” stated Brian M. Culley, Lineage CEO. “In certain rare conditions, raising investor awareness can lead to greater investment, which can help to accelerate new treatments. This funding will enable this year’s symposium to continue to foster open and collaborative dialogue among leading experts, companies, researchers, persons with lived experience, caregivers, advocacy organizations, regulators and members of the investment community."

Current confirmed speakers and moderating healthcare analysts (subject to change), include:

• Richard G. Fessler, M.D., Ph.D., Professor, Department of Neurosurgery, RUSH University Medical Center
• James D. Guest, M.D., Ph.D., Clinical Professor, Department of Neurological Surgery, The Miami Project to Cure Paralysis, Professor, University of Miami Miller School of Medicine
• Mary Jane "MJ" Mulcahey, Ph.D., OTR/L, CPPC, CLCP, FASIA, Professor, Department of Occupational Therapy, Director, Center for Outcomes and Measurement, Professor, Department of Rehabilitation Medicine, Sidney Kimmel Medical College, Thomas Jefferson University
• Steven Kirshblum, M.D., Chief Medical Officer, Kessler Foundation, Professor of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School
• Marco Baptista, Ph.D., Chief Scientific Officer, Christopher & Dana Reeve Foundation
• Jerod & Hanna Nieder, Positively Paralyzed LLC
• Jack Allen, CFA, Senior Research Analyst, Biotechnology, R.W. Baird & Co., Inc.
• Joseph Pantginis, Ph.D., Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., Inc.

Additional presenters (subject to change), include: